Company Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States.
The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 2013 |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 800 |
| CEO | Christopher Gibson |
Contact Details
Address: 41 South Rio Grande Street Salt Lake City, Utah 84101 United States | |
| Phone | 385 269 0203 |
| Website | recursion.com |
Stock Details
| Ticker Symbol | RXRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001601830 |
| CUSIP Number | 75629V104 |
| ISIN Number | US75629V1044 |
| Employer ID | 46-4099738 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Ben R. Taylor | Chief Financial Officer and President of Recursion UK |
| Dr. David J. Mauro M.D., Ph.D. | Chief Medical Officer |
| Dr. Najat Khan Ph.D. | Chief Research & Development Officer, Chief Commercial Officer and Director |
| Kristen Rushton M.B.A. | Chief Operating Officer |
| Kevin Leggat | Vice President of Finance and Accounting |
| Benjamin Mabey M.S. | Chief Technology Officer |
| Dr. David Hallett Ph.D. | Chief Scientific Officer |
| Nathan Hatfield J.D., M.B.A. | Chief Legal Officer and General Counsel |
| Erica Fox | Chief People and Impact Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 8-K | Current Report |
| May 9, 2025 | 424B7 | Filing |
| May 5, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 5, 2025 | 10-Q | Quarterly Report |
| May 5, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | 144 | Filing |
| Mar 18, 2025 | 8-K | Current Report |